Masilukast

Drug Profile

Masilukast

Alternative Names: D 3523; ICI D 3523; MCC-847; SA09012; ZD 3523

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer Mitsubishi Tanabe Pharma Corporation; SAMA Pharmaceuticals
  • Class Antiasthmatics; Bronchodilators; Indoles
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • Discontinued Allergic rhinitis

Most Recent Events

  • 11 Sep 2015 Phase-II development for Asthma is ongoing in South Korea
  • 15 Nov 2012 Masilukast licensed to SAMA Pharmaceuticals in South Korea
  • 15 Nov 2012 Phase-II clinical trials in Asthma in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top